Related Experiment Videos
A new platform for oligonucleotide delivery utilizing the PEG prodrug approach
Hong Zhao1, Richard B Greenwald, Prasanna Reddy
1Enzon Pharmaceuticals Inc., 20 Kingsbridge Road, Piscataway, New Jersey 08854, USA. hong.zhao@enzon.com
Bioconjugate Chemistry
|July 21, 2005
Summary
PEGylation of oligonucleotides (ODNs) significantly enhances their stability and plasma half-life. This prodrug approach improves pharmacokinetic properties, offering a promising strategy for ODN drug development.
Area of Science:
- Oligonucleotide chemistry
- Drug delivery systems
- Pharmacokinetics
Background:
- Oligonucleotides (ODNs) face challenges in vivo due to rapid degradation by nucleases.
- Enhancing ODN stability and pharmacokinetic profiles is crucial for therapeutic applications.
- Genasense (GS), an ODN candidate, was selected as a model for modification.
Purpose of the Study:
- To synthesize and evaluate PEG-modified ODN prodrugs.
- To assess the impact of PEGylation on ODN stability and pharmacokinetic properties.
- To develop a robust synthesis for ODN-dye conjugates.
Main Methods:
- Solid-state synthesis of aminohexyl-functionalized ODNs (1 and 4).
- Conjugation of releasable polyethylene glycol (rPEG) moieties to amino-ODNs.
- In vitro and in vivo pharmacokinetic studies in rats.
- Synthesis of ODN-dye conjugates using orthogonal protecting groups.
Main Results:
- PEG-modified oligos demonstrated significantly increased rat plasma half-life.
- Enhanced stability against mammalian nucleases, particularly PEII, was observed.
- Pharmacokinetic studies showed improved C(max), half-life, and AUC for PEGylated ODNs compared to unmodified GS.
- Successful synthesis of ODN-dye conjugates was achieved.
Conclusions:
- PEGylation is an effective strategy to improve ODN stability and pharmacokinetic profiles.
- The developed prodrug approach offers a viable method for enhancing ODN therapeutic potential.
- The synthesis methodology is suitable for creating labeled ODN prodrugs.